Centene (CNC): Medicaid Margin Recovery Is Gaining Traction

Thesis

Centene(CNC) is a medium-term recovery story built on one simple fact pattern: the business just posted a strong Q1 2026 beat-and-raise quarter, but the stock still trades at a modest forward earnings multiple and a very low enterprise-value-to-revenue ratio. On April 28, 2026, Centene reported Q1 revenue of $49.944B, premium and service revenue of $44.655B, GAAP EPS of $3.11, and adjusted EPS of $3.37. Management then raised full-year 2026 adjusted EPS guidance to greater than $3.40 from greater than $3.00 and lifted premium and service revenue guidance by $1.0B to $171.0B-$175.0B. That is not the profile of a business in free fall. It is the profile of a company clawing back margin after a rough 2025.

The investment case rests on three pillars. First, Medicaid remains a massive and durable core franchise. Centene generated $147.644B of 2025 revenue from Medicaid, equal to 75.8% of total revenue, and management said Q1 2026 Medicaid HBR improved 50 bps YoY to 93.1%. Second, Medicare and PDP performance improved faster than expected, with segment HBR at 84.9% in Q1 2026 and management pointing to a path to Medicare Advantage breakeven in 2027. Third, the balance sheet is sturdier than the headline 2025 net loss implies, with $17.888B of cash against $18.777B of total debt and a 2025 current ratio of 1.68.

The risk is equally clear. Centene lost $6.67B in 2025, net margin was -3.4%, trailing EPS was -$14.07, and return on equity was -28.68%. This is not a clean compounder. It is an operator in a regulated spread business where pricing accuracy, state rate adequacy, and medical cost trend decide whether margins hum or break. For a balanced, moderate-risk investor, that makes Centene more of a selective Buy than a blind conviction bet. The stock looks mispriced relative to improving operating facts, but it still needs to prove that 2026 is the start of a durable earnings reset rather than a temporary rebound.

Company Overview

Centene(CNC) is a managed care company headquartered in St. Louis, Missouri, with 61,100 employees. It operates across Medicaid, Medicare, Commercial, and Other, serving under-insured families, government-sponsored populations, and commercial organizations in the U.S. The company was founded in 1984 and has built its identity around government-sponsored healthcare, especially Medicaid managed care.

The business model is straightforward in concept and unforgiving in execution. Centene collects premium revenue, manages provider networks and medical services, and tries to keep medical costs and administrative costs below premium intake. That is why the health benefits ratio, or HBR, matters so much. In Q1 2026, consolidated HBR was 87.3%, which helped drive adjusted EPS of $3.37. When HBR improves, the earnings engine starts to work. When HBR drifts the wrong way, even huge revenue can produce ugly bottom-line results.

Centene’s scale is real. As of Dec. 31, 2024, the company served 13 million Medicaid recipients in 30 states, 1.1 million Medicare Advantage members across 37 states, and had 25.9 million at-risk members plus 2.7 million TRICARE eligibles. That scale gives it purchasing leverage, administrative reach, and credibility in state bidding. It also makes the company deeply exposed to government reimbursement and policy shifts. In managed care, scale is both armor and gravity.

Business Segment Deep Dive

Medicaid is the center of gravity. In 2025, the Medicaid segment generated $147.644B of revenue, or 75.8% of total company revenue, up from $124.449B in 2024. Management said Q1 2026 Medicaid membership ended at 12.4 million and segment HBR improved to 93.1%, 50 bps better than Q1 2025. Sarah London said this marked the third consecutive quarter of progress toward restoring a reasonable Medicaid margin. That matters because Medicaid is large enough to move the whole company. If this segment stabilizes, the earnings base stabilizes with it.

Commercial is smaller but strategically important. The Commercial segment produced $42.003B of revenue in 2025, or 21.6% of total revenue, up from $33.702B in 2024. The vast majority of this segment is Marketplace. In Q1 2026, Marketplace membership ended at 3.58 million, and management said pretax earnings were on track despite slightly higher-than-expected HBR because SG&A outperformed. The issue inside Commercial is not demand. It is morbidity mix and risk adjustment. Management said Silver-tier members showed higher acuity, but also said the company now expects a slight year-end risk transfer receivable rather than a payable forecast.

Other remains small in reported segment revenue, with $5.13B in 2025, or 2.6% of total revenue. But the strategic importance is larger than the revenue share implies because this bucket includes clinical services, pharmacies, vision, dental, behavioral health, and centralized services. These functions support network management, care coordination, and cost control across the broader enterprise. In a business where a few dozen basis points in medical cost trend can change earnings materially, support capabilities are not back-office decoration. They are part of the machine.

Medicare is discussed extensively by management even though the annual segment breakout provided here does not isolate it as a standalone revenue line. In Q1 2026, Medicare HBR was 84.9%, ahead of expectations, with outperformance in both Medicare Advantage and PDP. The PDP business ended the quarter with just over 8.7 million members, and management said Medicare Advantage is on a path to breakeven in 2027. That is important because Medicare has been a source of pressure across the industry. Better-than-planned performance here gives Centene a second leg of recovery beyond Medicaid.

Flagship Product Analysis

Centene’s flagship product is effectively its Medicaid managed care offering, because that is where the company has its deepest scale, broadest state footprint, and largest revenue contribution. Medicaid generated $147.644B of 2025 revenue and remains the company’s defining franchise. The product is not glamorous, but it is sticky, local, and operationally dense. States care about quality, provider access, administrative capability, and cost control. Centene has spent decades building those muscles.

The current operating story in Medicaid is margin recovery. Sarah London said Centene is modernizing and standardizing processes to better manage medical cost trend, while Andrew Asher said the company’s initiatives on both revenue and medical expense are bearing fruit. Q1 2026 Medicaid HBR of 93.1% improved 50 bps YoY, and management still expects a composite rate yield of roughly 4.5% for 2026. In plain English, the company is trying to get paid more appropriately for a sicker population while also tightening cost discipline. That is the whole game.

Ambetter, the company’s Marketplace platform, is the other product worth close attention. Management said Ambetter retained Silver membership with higher acuity relative to the market and that this population should receive a meaningful risk adjustment offset. In Q1 2026, Marketplace ended with just under 3.6 million members, with just under half in Silver, roughly 35% in Bronze, and the remainder in Gold. That mix matters because Marketplace profitability depends on pricing and risk adjustment precision. It is a product where the actuarial math can either print cash or hand the market a headache.

Innovation & Competitive Advantage

Centene’s moat is not a consumer brand moat. It is a regulatory, operational, and scale moat. The company is the largest Medicaid health insurer in the U.S., and that matters because Medicaid is state-by-state, contract-driven, and hard to replicate quickly. The advantage comes from provider networks, local relationships, claims infrastructure, and the ability to bid and operate at scale across many states.

Management’s recent comments show where Centene is trying to widen that moat. Sarah London described a multipronged trend program that includes standardized utilization management, expanded clinical programs, data-driven network optimization, and more aggressive fraud, waste, and abuse controls. Andrew Asher added that Centene is deploying advanced analytics and selective AI-enabled tools across forecasting, medical economics, and payment integrity. In managed care, innovation is less about shiny apps and more about finding expensive claims before they become permanent habits.

The company also has a structural advantage in dual-eligible and integrated care positioning. Management said Medicare Advantage membership is being aligned with Centene’s Medicaid footprint, and industry context shows CMS rules will increasingly push more integrated care for duals starting in 2027 and 2030. Centene’s overlap between Medicaid and Medicare gives it a practical edge here. That overlap can improve retention, care coordination, and long-term economics if execution holds.

Scale also shows up in SG&A. In Q1 2026, adjusted SG&A ratio was 7.6%, down from 7.9% a year earlier. The February 2026 guidance deck showed 2025 adjusted SG&A at 7.4%, down from 8.5% in 2024. Those are not dramatic numbers on their own, but in a low-margin business, a few tenths of a point are meaningful. This is a business where pennies are not pennies. They are architecture.

Operations & Supply Chain

For Centene, operations are the product. The company does not manufacture a physical good, so its equivalent of a supply chain is its provider network, claims processing system, pharmacy management, care management programs, and administrative platform. The 10-K describes centralized cash management and management-service functions that support restricted subsidiaries across personnel, rent, utilities, population health management, provider contracting, compliance, member services, claims processing, pharmacy oversight, IT, and finance. That centralized model supports scale but also requires tight control.

Management’s Q1 2026 commentary points to operational tightening in exactly the right places. In Medicaid, Centene is standardizing utilization management, expanding clinical programs, optimizing networks, and targeting fraud, waste, and abuse. In Medicare, management said it simplified contract structure and focused the portfolio on a partner ecosystem that can improve quality and cost outcomes. In Marketplace, the company worked with Wakely and peers to gain earlier visibility into membership demographics and risk transfer dynamics. That is a useful sign. Better data earlier in the year can reduce the kind of unpleasant surprises that wreck insurer credibility.

Claims reserves also deserve attention. Andrew Asher said medical claims liability totaled $20.6B in Q1 2026 and represented 48 days in claims payable, up 2 days from Q4 2025. That is a core operating metric because reserve accuracy drives earnings quality in managed care. The company also said faster-completing PDP business should drive days in claims payable down by a day or two as the year progresses. There is no obvious red flag in the data provided, but this remains an area investors should treat like the engine room, not the wallpaper.

Market Analysis

Centene operates in a large and durable market. Medicaid managed care alone covered over 66 million people as of July 2024, with managed care accounting for over $458B of Medicaid spending in FY2024. That is the core addressable market for Centene’s largest business. Medicare Advantage remains large as well, with 54% of eligible Medicare beneficiaries enrolled in MA in 2025. Marketplace remains meaningful, though more policy-sensitive, especially after the expiration of enhanced ACA premium tax credits on Dec. 31, 2025.

The managed care market is attractive in size but demanding in structure. It is fragmented in Medicaid, with states contracting with over 290 Medicaid MCOs as of July 2024. That means Centene’s scale helps, but it does not eliminate local competition. Reprocurement cycles remain a major battleground. Centene itself highlighted successful 2024 reprocurements in states including Florida, Michigan, and Kansas, while industry context notes several contracts are up for reprocurement in 2025 with many new contracts starting in 2026.

Industry trends are mixed but manageable. Special Needs Plans are growing, with SNPs reaching 21% of MA enrollment in 2025, up from 14% in 2020. That supports Centene’s dual-eligible strategy. At the same time, pricing and utilization pressure remain elevated across managed care. McKinsey cited about 7% higher medical costs from utilization and IRA-related Part D pressure in 2024. That backdrop explains why Centene’s Q1 2026 Medicare outperformance matters. In a tough industry tape, better-than-expected HBR is not luck by default. It usually means the operator did something right.

Customer Profile

Centene’s customer base is concentrated in government-sponsored healthcare. The end user is the member, but the economic customer is often the state Medicaid agency, CMS-linked program, or exchange structure that determines reimbursement and rules. That gives the company a very different customer profile from a typical commercial insurer. It is less dependent on employer benefits cycles and more dependent on public policy, bid discipline, and medical cost management.

In Medicaid, Centene serves low-income families, children, aged, blind, or disabled populations, and members needing long-term services and supports. In Medicare, it serves MA, special needs, supplement, and PDP members. In Commercial, Marketplace dominates. Management said Marketplace ended Q1 2026 with 3.58 million members and that 75% of Silver-tier members were renewals, which gave the company a high degree of visibility into year-over-year risk score capture. That renewal base matters because returning members are easier to price and manage than a fresh pool of unknowns.

The customer profile also shapes investor expectations. These are not discretionary consumers buying a premium brand. They are members in regulated programs where affordability, access, and compliance matter more than marketing gloss. That tends to make revenue durable but margins politically and actuarially constrained. It is a stable demand pool with unstable economics if management loses the plot.

Competitive Landscape

Centene competes against UnitedHealth(UNH), Elevance Health(ELV), Humana(HUM), Molina Healthcare(MOH), and a long tail of regional and local Medicaid MCOs. The competitive map is product-specific. UnitedHealth and Humana are stronger in Medicare Advantage scale. Elevance is broad across commercial, Medicaid, and Medicare. Molina is a more direct government-program peer, especially in Medicaid and Marketplace. Centene’s edge is deepest in Medicaid scale and state-level execution.

The company’s competitive position is strongest where local execution and contract relationships matter more than national branding. States evaluate bids based on quality of care, provider networks, cost reduction, and administrative capability. Centene’s long operating history, broad state footprint, and provider infrastructure create switching friction. That is a real advantage, but not an untouchable one. Medicaid contracts can be rebid, and poor pricing discipline can turn a market share win into a margin trap.

Relative to larger diversified peers, Centene is more exposed to Medicaid and ACA Marketplace and less diversified into employer commercial and care-delivery services. That makes the stock more sensitive to state rate-setting, redeterminations, and subsidy policy changes. The upside is that if Medicaid rates normalize and Marketplace risk adjustment lands favorably, Centene’s earnings can recover faster than the market expects. The downside is that the same concentration can punish the stock quickly if policy or trend moves the other way.

Macro & Geopolitical Landscape

Centene’s macro exposure is less about GDP and more about public budgets, healthcare inflation, and federal rulemaking. The most important macro variable for the company is medical cost trend relative to reimbursement. Management said 2026 Medicaid net trend is expected to remain in the mid-4% range and that composite rate yield is tracking around 4.5%. That narrow spread tells the story. When rates and trend are aligned, margins can recover. When they diverge, the model strains.

Policy remains a major force. The 2024 annual report noted that enhanced ACA premium tax credits expire Dec. 31, 2025 unless renewed or extended. Management said the post-APTC environment drove expected market contraction and a shift from Silver into Bronze and Gold in Marketplace. In Medicare, finalized 2027 MA rates improved versus the advance notice, but management still said the final rate remains below observed medical cost trend. In other words, the company is operating in a world where public reimbursement is improving in places but still not exactly generous.

There is limited direct geopolitical exposure in the classic sense. Centene is a domestic healthcare payer. Its real geopolitical risk is U.S. policy risk: CMS rules, state Medicaid budgets, subsidy design, and program integrity reforms. That is less dramatic than tariffs and shipping lanes, but for this stock it is far more important. A managed care company can survive a noisy macro headline. It cannot ignore a reimbursement formula.

Balance Sheet Health

Income Statement Strength

Estimates Outlook

Valuation Assessment

Target Prices & Recommendation

Closing

Centene(CNC) is not a simple story, and that is exactly why the opportunity exists. The company came through 2025 with a badly bruised income statement, but it entered 2026 with a stronger balance sheet posture, better cash generation, and clear evidence of operating improvement. Q1 2026 delivered $49.944B of revenue, $3.37 of adjusted EPS, and a higher full-year outlook. Medicaid HBR improved, Medicare outperformed, and SG&A stayed disciplined.

For a moderate-risk investor with a medium-term horizon, the stock looks more attractive than the headline scars imply. The market is still pricing Centene with skepticism, and some skepticism is deserved. But a forward P/E of 14.0x, a PEG below 1.0, a consensus target above the current trading zone, and a fair value estimate of $45 create a favorable risk-reward profile if management keeps executing. This is not a stock for investors who need perfect visibility. It is a stock for investors willing to buy a large, cash-generative healthcare operator while the recovery is still being argued over.

The bottom line: Centene is a Buy, not because the business is flawless, but because the latest facts show it is improving faster than the valuation gives it credit for. In markets, that gap is where returns usually start.